 |
JOURNAL TOOLS |
| Publishing options |
| eTOC |
| To subscribe |
| Submit an article |
| Recommend to your librarian |
ARTICLE TOOLS |
| Reprints |
| Permissions |
| Share |
YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
GYNECOLOGICAL ENDOCRINOLOGY
Minerva Endocrinologica 2014 September;39(3):155-65
Copyright © 2014 EDIZIONI MINERVA MEDICA
language: English
Endometriosis and ovarian cancer: clinical and molecular aspects
Pavlidou A. 1, Vlahos N. F. 1, 2 ✉
1 Second Department of Obstetrics and Gynecology, University of Athens Medical School, Aretaieion Hospital, Athens, Greece; 2 Department of Gynecology and Obstetrics, Johns Hopkins Hospital School of Medicine, Baltimore, MD, USA
Endometriosis is one of the most commonly encountered benign problems in gynecology. Even though endometriosis appears to predispose to ovarian cancer the progression from atypical epithelial proliferation (atypical endometriosis and metaplasia), to the formation of well-defined borderline tumors and finally to endometrioid ovarian cancer will take several years. To elaborate on the concept of endometriosis as a precursor of some types of ovarian cancer, we present an overview of the pathophysiological and genetic characteristics, common in those two conditions. Furthermore, we present the genetic mutations found in ovarian cancers and we outline the common genetic alterations of endometriosis and ovarian cancer, focusing on the PI3K/Akt/mTOR-signaling pathway.